Positive first IPO results from Sweden’s Immunovia

Time for weighing things up for Sweden-based Immunovia, which had its Nasdaq debut exactly a month ago. Its shares have risen over 10% since then, and the group’s capitalization has risen from €214m to €247m. Immunovia AB was created in 2007 by a group of scientists from the Immunology Department of Lund University and CREATE Health (Center for Translational Cancer Research Lund) and currently has 40 employees.